



MEN

**FIRST CANCER SITE  
MESOTHELIOMA**
**MESOTHELIOMA  
POOL AIRTUM 1976-2010, MEN:**

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

**MESOTELIOMA  
POOL AIRTUM 1976-2010, UOMINI:**

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	3832		4368		4368		3832		1702		130		28		3832	4368
Person-years ▶	4605		5289		684		2208		1983		298		116		4605	5289
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND MESOTHELIOMA	58	0.65	76	0.74	18	1.28	24	0.55	29	0.77	5	0.90	0	0.00	-6.75	-5.14
HEAD AND NECK	2	0.51	2	0.44	0	0.00	0	0.00	2	1.20	0	0.00	0	0.00	-0.42	-0.48
ORAL CAVITY	1	1.07	1	0.93	0	0.00	0	0.00	1	2.53	0	0.00	0	0.00	0.01	-0.01
PHARYNX	1	1.14	1	0.99	0	0.00	0	0.00	1	2.67	0	0.00	0	0.00	0.03	0.00
LARYNX	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.46	-0.47
OESOPHAGUS	1	1.00	1	0.86	0	0.00	0	0.00	1	2.36	0	0.00	0	0.00	0.00	-0.03
STOMACH	7	1.39	8	1.37	1	1.21	2	0.80	5	2.38	0	0.00	0	0.00	0.43	0.41
COLON RECTUM	7	0.58	8	0.58	1	0.53	4	0.68	2	0.40	1	1.32	0	0.00	-1.09	-1.12
COLON	5	0.61	6	0.63	1	0.77	3	0.74	1	0.29	1	1.90	0	0.00	-0.71	-0.67
RECTUM	2	0.53	2	0.46	0	0.00	1	0.54	1	0.63	0	0.00	0	0.00	-0.38	-0.44
LIVER	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.80	-0.81
GALLBLADDER	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.20	-0.20
PANCREAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.52	-0.53
LUNG	4	0.25	13	0.71	9	3.55	3	0.38	1	0.15	0	0.00	0	0.00	-2.55	-1.00
SKIN MELANOMA	0	0.00	1	0.67	1	5.20	0	0.00	0	0.00	0	0.00	0	0.00	-0.28	-0.09
MESOTHELIOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.11	-0.11
KAPOSI SARCOMA	1	5.37	1	4.62	0	0.00	0	0.00	1	12.76	0	0.00	0	0.00	0.18	0.15
SOFT TISSUE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.07	-0.07
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
BREAST	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
PROSTATE	16	0.90	20	0.97	4	1.44	8	0.92	5	0.66	3	2.54	0	0.00	-0.41	-0.12
TESTIS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
KIDNEY AND RENAL PELVIS	5	1.76	7	2.13	2	4.57	2	1.44	3	2.49	0	0.00	0	0.00	0.47	0.70
BLADDER AND URINARY TRACT	5	0.51	5	0.44	0	0.00	2	0.42	3	0.73	0	0.00	0	0.00	-1.03	-1.19
URINARY BLADDER	5	0.54	5	0.46	0	0.00	2	0.44	3	0.77	0	0.00	0	0.00	-0.93	-1.09
URINARY TRACT	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.09	-0.09
BRAIN AND CENTRAL NERVOUS SYSTEM	2	1.93	2	1.67	0	0.00	0	0.00	2	4.55	0	0.00	0	0.00	0.21	0.15
THYROID	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.09	-0.09
HODGKIN LYMPHOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
NON-HODGKIN LYMPHOMA	1	0.39	1	0.34	0	0.00	1	0.80	0	0.00	0	0.00	0	0.00	-0.34	-0.37
MYELOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.25	-0.25
LEUKAEMIAS	4	2.04	4	1.75	0	0.00	1	1.03	2	2.43	1	8.31	0	0.00	0.44	0.33
LYMPHOID LEUKAEMIAS	1	1.04	1	0.90	0	0.00	0	0.00	1	2.47	0	0.00	0	0.00	0.01	-0.02
MYELOID LEUKAEMIAS	2	2.27	2	1.96	0	0.00	1	2.30	0	0.00	1	18.36	0	0.00	0.24	0.18
OTHER LEUKAEMIAS	1	8.20	1	7.00	0	0.00	0	0.00	1	19.64	0	0.00	0	0.00	0.19	0.16
OTHER AND ILL DEFINED SITES	3	0.68	3	0.58	0	0.00	1	0.46	2	1.07	0	0.00	0	0.00	-0.31	-0.41

Decrease/Difetto  
Increase/Eccesso

O Observed cases  
Casi osservati

SIR Standardized Incidence Ratio  
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk  
Eccesso assoluto di rischio



**WOMEN** FIRST CANCER SITE  
**MESOTHELIOMA**

**MESOTHELIOMA**  
**POOL AIRTUM 1976-2010, WOMEN:**

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

**MESOTELIOMA**  
**POOL AIRTUM 1976-2010, DONNE:**

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	1466		1689		1689		1466		668		81		18		1466	1689
Person-years ▶	1987		2251		264		848		886		181		72		1987	2251
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND MESOTHELIOMA	25	1.19	29	1.20	4	1.32	11	1.17	12	1.32	2	1.14	0	0.00	1.97	2.16
HEAD AND NECK	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.14	-0.14
ORAL CAVITY	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.07	-0.07
PHARYNX	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
LARYNX	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
OESOPHAGUS	2	20.16	2	17.49	0	0.00	0	0.00	2	47.37	0	0.00	0	0.00	0.96	0.84
STOMACH	1	0.93	1	0.80	0	0.00	0	0.00	1	2.23	0	0.00	0	0.00	-0.04	-0.11
COLON RECTUM	2	0.64	2	0.56	0	0.00	1	0.71	1	0.75	0	0.00	0	0.00	-0.56	-0.70
COLON	2	0.89	2	0.78	0	0.00	1	0.98	1	1.05	0	0.00	0	0.00	-0.12	-0.25
RECTUM	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.44	-0.45
LIVER	1	1.84	1	1.60	0	0.00	1	3.95	0	0.00	0	0.00	0	0.00	0.23	0.17
GALLBLADDER	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.21	-0.21
PANCREAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.40	-0.41
LUNG	0	0.00	1	0.64	1	5.07	0	0.00	0	0.00	0	0.00	0	0.00	-0.69	-0.25
SKIN MELANOMA	1	2.48	1	2.19	0	0.00	0	0.00	0	0.00	1	27.79	0	0.00	0.30	0.24
MESOTHELIOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
KAPOSI SARCOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
SOFT TISSUE	1	11.34	1	9.93	0	0.00	1	25.65	0	0.00	0	0.00	0	0.00	0.46	0.40
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
BREAST	3	0.52	4	0.62	1	1.30	2	0.81	1	0.40	0	0.00	0	0.00	-1.37	-1.11
CERVIX UTERI	2	6.93	2	6.08	0	0.00	1	7.92	1	7.78	0	0.00	0	0.00	0.86	0.74
CORPUS UTERI	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.53	-0.53
OVARY	2	2.93	3	3.86	1	10.50	1	3.33	1	3.36	0	0.00	0	0.00	0.66	0.99
KIDNEY AND RENAL PELVIS	2	3.84	3	5.05	1	13.51	0	0.00	2	8.86	0	0.00	0	0.00	0.74	1.07
BLADDER AND URINARY TRACT	1	1.31	1	1.13	0	0.00	1	2.85	0	0.00	0	0.00	0	0.00	0.12	0.05
URINARY BLADDER	1	1.40	1	1.22	0	0.00	1	3.06	0	0.00	0	0.00	0	0.00	0.14	0.08
URINARY TRACT	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
BRAIN AND CENTRAL NERVOUS SYSTEM	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.16	-0.16
THYROID	1	2.36	1	2.11	0	0.00	0	0.00	1	5.26	0	0.00	0	0.00	0.29	0.23
HODGKIN LYMPHOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
NON-HODGKIN LYMPHOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.40	-0.41
MYELOMA	1	2.80	1	2.44	0	0.00	0	0.00	0	0.00	1	36.44	0	0.00	0.32	0.26
LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.24	-0.25
LYMPHOID LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.11	-0.11
MYELOID LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.12	-0.12
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
OTHER AND ILL DEFINED SITES	5	2.86	5	2.47	0	0.00	3	3.10	2	3.41	0	0.00	0	0.00	1.31	1.06

Decrease/Difetto / Increase/Eccesso    O Observed cases / Casi osservati    SIR Standardized Incidence Ratio / Rapporto standardizzato di incidenza    EAR Excess Absolute Risk / Eccesso assoluto di rischio